The Alternative Bank has unveiled a new non-interest financing initiative aimed at supporting local pharmaceutical production in Nigeria as the country intensifies efforts to reduce dependence on imported medicines. The programme is designed to provide ethical financing solutions for manufacturers seeking to expand domestic drug production capacity, according to Vanguard News and Punch.
The initiative aligns with growing national efforts to strengthen Nigeria’s healthcare value chain and improve access to locally manufactured medicines. Industry stakeholders have repeatedly called for targeted financing support to help pharmaceutical companies manage rising production costs, foreign exchange pressures, and supply chain challenges, as highlighted by Nairametrics and healthcare industry groups.
AltBank said the financing model will use Sharia-compliant structures that avoid conventional interest-based lending while supporting long-term industrial development. The bank has recently expanded its non-interest financing capacity through partnerships with institutions such as the Islamic Trade Finance Corporation, securing a $15 million Murabaha financing line to support key sectors of the Nigerian economy.
Analysts say increased access to ethical and affordable financing could help Nigerian pharmaceutical manufacturers scale production, create jobs, and improve medicine availability across the country. The move also reflects broader momentum within Nigeria’s financial sector to channel more capital into healthcare, manufacturing, and import-substitution industries as part of wider economic diversification efforts.
